Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience |
Jeong, Jae-Uk
(Department of Radiation Oncology, Chonnam National University Hwasun Hospital)
Chung, Woong-Ki (Department of Radiation Oncology, Chonnam National University Hwasun Hospital) Nam, Taek-Keun (Department of Radiation Oncology, Chonnam National University Hwasun Hospital) Yang, Deok-Hwan (Department of Hematology-Oncology, Chonnam National University Hwasun Hospital) Ahn, Sung-Ja (Department of Radiation Oncology, Chonnam National University Hwasun Hospital) Song, Ju-Young (Department of Radiation Oncology, Chonnam National University Hwasun Hospital) Yoon, Mee Sun (Department of Radiation Oncology, Chonnam National University Hwasun Hospital) Kim, Yong-Hyeob (Department of Radiation Oncology, Chonnam National University Hwasun Hospital) |
1 | Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41. DOI |
2 | Yu JI, Nam H, Ahn YC, Kim WS, Park K, Kim SJ. Involved-lesion radiation therapy after chemotherapy in limited-stage headand-neck diffuse large B cell lymphoma. Int J Radiat Oncol Biol Phys 2010;78:507-12. DOI |
3 | Campbell BA, Connors JM, Gascoyne RD, Morris WJ, Pickles T, Sehn LH. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer 2012;118:4156-65. DOI |
4 | Krol AD, Berenschot HW, Doekharan D, Henzen-Logmans S, van der Holt B, van 't Veer MB. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy. Radiother Oncol 2001;58:251-5. DOI |
5 | Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011;100:86-92. DOI |
6 | Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015;92:11-31. DOI |
7 | Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26. DOI |
8 | Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977;61:1023-7. |
9 | Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-Bcell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91. DOI |
10 | Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16. DOI |
11 | Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86. DOI |
12 | Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6. DOI |
13 | Nathu RM, Mendenhall NP, Almasri NM, Lynch JW. Non-Hodgkin's lymphoma of the head and neck: a 30-year experience at the University of Florida. Head Neck 1999;21:247-54. DOI |
14 | Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032-8. DOI |
15 | Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170-6. DOI |
16 | Kwon J, Kim IH, Kim BH, Kim TM, Heo DS. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys 2015;92:91-8. DOI |
17 | National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2011 [cited 2017 Nov 27]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp/PDF/b-cell.pdf |
18 | Kaplan HS. Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis. Cancer 1980;45:2439-74. DOI |
19 | Verhappen MH, Poortmans PM, Raaijmakers E, Raemaekers JM. Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma. Radiother Oncol 2013;109:133-9. DOI |
20 | Wilder RB, Tucker SL, Ha CS, et al. Dose-response analysis for radiotherapy delivered to patients with intermediategrade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 2001;49:17-22. DOI |